| Field |
Value |
| Experiment ID |
DLB-GENETIC-MODIFIERS-001 |
| Category |
Translational / Biomarker |
| Disease |
Dementia with Lewy Bodies |
| Rank |
109 |
| Score |
72 |
How do genetic risk factors (GBA, SNCA, APOE, and polygenic risk) modify the clinical phenotype, disease progression, and treatment response in DLB? Can genetic information guide personalized treatment selection?
-
GBA carriers present with:
- Earlier age of onset
- More severe autonomic dysfunction
- Faster progression
- Reduced response to cholinesterase inhibitors
-
SNCA promoters influence:
- Severity of visual hallucinations
- Disease severity correlates with expression levels
-
APOE genotype modifies:
- Tau co-pathology burden
- Cognitive reserve capacity
- Response to immunotherapy approaches
- Type: Genetic association with longitudinal phenotyping
- Cohort: 500 genetically characterized DLB patients
- 100 GBA carriers (50 heterozygous, 50 severe)
- 150 SNCA promoter variants
- 150 APOE carriers (50 E4/E4, 100 E4/E3)
- 100 non-carriers as control
- Follow-up: 3 years
-
GBA sequencing
- Full gene sequencing for pathogenic variants
- Enzyme activity assay (beta-glucocerebrosidase)
-
SNCA analysis
- Promoter variability (Rep1, Rep2)
- Copy number variation
- Expression quantitative trait loci
-
APOE genotyping
- rs429358 and rs7412
- Plasma ApoE levels
-
Polygenic risk score
- AD PRS
- PD PRS
- DLB-specific PRS (to be developed)
- Comprehensive cognitive testing at baseline and annually
- Motor assessment (UPDRS)
- Psychiatric evaluation (NPI, BPRS)
- Autonomic function testing
- MRI volumetry
- CSF and blood biomarkers
- iPSC-derived neurons from GBA-DLB patients
- GBA knock-in mouse models
- Alpha-synuclein transgenic models with APOE4
- Primary: Define genotype-phenotype correlations for each genetic modifier
- Secondary: Develop genetic stratification algorithm for clinical trials
- Exploratory: Identify interaction between genetic modifiers and treatment response
| Dimension |
Score |
Notes |
| Technical |
9/10 |
Established genetic screening, large DLB cohorts exist |
| Recruitment |
8/10 |
International DLB genetics consortia available |
| Cost |
7/10 |
$3M over 3 years, genotyping costs decreasing |
| Timeline |
8/10 |
3-year study feasible |
Estimated Cost: $2.8-3.2M over 3 years
Estimated Duration: 24 months enrollment + 12 months follow-up
| Genetic Factor |
Clinical Implication |
| GBA severe variants |
Consider experimental therapies targeting glucocerebrosidase |
| APOE E4/E4 |
Caution with amyloid immunotherapy; consider anti-tau approaches |
| High PRS |
Earlier intervention; more aggressive disease modification |
| SNCA variants |
May predict better response to alpha-synuclein targeting |